Internal Medicine, Hematology & Oncology · Jackson, MS
NPI
1790780716
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
2969 Curran Dr N, Ste 200
Jackson, MS, 39216
Phone (601) 974-5600
Groups this clinician bills Medicare through
Medicare paid, 2024
$12.4M
647,096 services
Medicare patients, 2024
1,208
Average age 74
Drug cost, 2024
$8.8M
2,813 prescriptions
Company payments, 2025
$10K
From 43 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Guangzhi Qu was code J9299 (injection, nivolumab, 1 mg), 60,040 times for 35 patients. In total Guangzhi Qu billed 647,096 services in 198 codes, and Medicare paid $12.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-04-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9299 Injection, nivolumab, 1 mg | Office | 60,040 | 35 | $23.71 | $1.4M |
| J9271 Injection, pembrolizumab, 1 mg | Office | 43,800 | 36 | $41.97 | $1.8M |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 32,830 | 78 | $36.61 | $1.2M |
| J0185 Injection, aprepitant, 1 mg | Office | 28,730 | 67 | $1.28 | $37K |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 26,250 | 20 | $0.87 | $23K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 24,552 | 72 | $20.22 | $496K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 24,300 | 19 | $37.54 | $912K |
| J0897 Injection, denosumab, 1 mg | Office | 18,900 | 79 | $20.43 | $386K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 18,600 | 15 | $0.04 | $804 |
| J9264 Injection, paclitaxel protein-bound particles, 1 mg | Office | 16,500 | 26 | $10.51 | $173K |
| J9041 Injection, bortezomib, 0.1 mg | Office | 10,080 | 23 | $1.36 | $14K |
| J9267 Injection, paclitaxel, 1 mg | Office | 9,540 | 13 | $0.08 | $753 |
| J9047 Injection, carfilzomib, 1 mg | Office | 9,220 | 13 | $38.05 | $351K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 7,003 | 121 | $0.09 | $614 |
| J1930 Injection, lanreotide, 1 mg | Office | 6,600 | 13 | $37.33 | $246K |
By year: 2022 $11.0M for 812,581 services; 2023 $13.7M for 801,310 services; 2024 $12.4M for 647,096 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 4,692 | 990 | $7.46 | $35K |
| 80053 Clinical Chemistry | 3,954 | 970 | $10.15 | $40K |
| 36415 Venipuncture Blood Collection | 3,133 | 884 | $8.45 | $26K |
| 83521 Immunoassay | 1,938 | 206 | $16.83 | $33K |
| 82728 Clinical Chemistry | 1,040 | 598 | $13.15 | $14K |
| 83550 Clinical Chemistry | 1,004 | 587 | $8.43 | $8,463 |
| 83540 Clinical Chemistry | 1,004 | 587 | $6.23 | $6,258 |
| 82784 Immunoassay | 688 | 127 | $9.09 | $6,252 |
| 84443 Clinical Chemistry | 671 | 115 | $16.44 | $11K |
| 85055 Blood Count | 361 | 164 | $33.95 | $12K |
Medicare prescription drug claims, 2024
In 2024, the drug Guangzhi Qu prescribed most often to Medicare patients was Acyclovir, with 294 prescriptions and refills. In total Guangzhi Qu wrote 2,813 Medicare prescriptions that cost $8.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 294 | 372 | 64 | $2,334 |
| Anastrozole Generic | 292 | 548 | 80 | $3,870 |
| Dexamethasone Generic | 150 | 181 | 38 | $2,921 |
| Ondansetron Odt Ondansetron | 100 | 102 | 67 | $1,595 |
| Potassium Chloride Generic | 99 | 133 | 41 | $961 |
| Ondansetron Hcl Generic | 87 | 87 | 54 | $982 |
| Imatinib Mesylate Generic | 83 | 91 | Under 11 | $92K |
| Promethazine Hcl Generic | 74 | 74 | 48 | $505 |
| Gabapentin Generic | 60 | 72 | 18 | $382 |
| Ninlaro Ixazomib Citrate | 57 | 57 | Under 11 | $694K |
| Eliquis Apixaban | 57 | 57 | Under 11 | $35K |
| Hydroxyurea Generic | 57 | 98 | 21 | $1,204 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 56 | 56 | 37 | $662 |
| Pomalyst Pomalidomide | 53 | 53 | Under 11 | $1.2M |
| Montelukast Sodium Generic | 51 | 51 | 13 | $163 |
Brand drugs: 668 claims; generic drugs: 2,145 claims; opioid claims: 57.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Guangzhi Qu $10K ($10K in general payments such as food, travel and fees) from 43 companies. The largest payer was Pfizer Inc. with $3,588.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 10 | $3,588 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $2,176 |
| BeOne Medicines USA, Inc. ONC | 4 | $2,011 |
| Janssen Biotech, Inc. JNJ | 6 | $276 |
| Celgene Corporation BMY | 10 | $230 |
| Gilead Sciences, Inc. GILD | 7 | $205 |
| Novartis Pharmaceuticals Corporation NVS | 11 | $204 |
| Merck Sharp & Dohme LLC MRK | 7 | $177 |
| Amgen Inc. AMGN | 1 | $103 |
| TerSera Therapeutics LLC | 3 | $99.13 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.